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Generic and Personalized RNAi-Based Therapeutics
for a Dominant-Negative Epidermal Fragility
Disorder
Deena M. Leslie Pedrioli1, Dun Jack Fu1, Emilio Gonzalez-Gonzalez2,3, Christopher H. Contag2,3,
Roger L. Kaspar3,4, Frances J.D. Smith1 and W.H. Irwin McLean1
Epidermolytic palmoplantar keratoderma (EPPK) is one of 430 autosomal-dominant human keratinizing
disorders that could benefit from RNA interference (RNAi)-based therapy. EPPK is caused by mutations in the
keratin 9 (KRT9) gene, which is exclusively expressed in thick palm and sole skin where there is considerable
keratin redundancy. This, along with the fact that EPPK is predominantly caused by a few hotspot mutations,
makes it an ideal proof-of-principle model skin disease to develop gene-specific, as well as mutation-specific,
short interfering RNA (siRNA) therapies. We have developed a broad preclinical RNAi-based therapeutic
package for EPPK containing generic KRT9 siRNAs and allele-specific siRNAs for four prevalent mutations.
Inhibitors were systematically identified in vitro using a luciferase reporter gene assay and validated using an
innovative dual-Flag/Strep-TagII quantitative immunoblot assay. siKRT9-1 and siKRT9-3 were the most potent
generic K9 inhibitors, eliciting485% simultaneous knockdown of wild-type and mutant K9 protein synthesis at
picomolar concentrations. The allele-specific inhibitors displayed similar potencies and, importantly, exhibited
strong specificities for their target dominant-negative alleles with little or no effect on wild-type K9. The most
promising allele-specific siRNA, siR163Q-13, was tested in a mouse model and was confirmed to preferentially
inhibit mutant allele expression in vivo.
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INTRODUCTION
RNA interference (RNAi) was first reported in plants just over
two decades ago (Napoli et al., 1990), and its subsequent
characterization in eukaryotic cells (Fire et al., 1998)
revolutionized the fields of molecular, cellular, and devel-
opmental biology, as well as molecular medicine. The
demonstration that small interfering RNAs (siRNAs) could
potently and specifically control the gene activity via
homology-dependent mRNA degradation suggested that
personalized, or allele-specific, therapeutics were theoreti-
cally attainable (Davidson and McCray, 2011). Monogenic
dominant-negative interference or gain-of-function disease
pathologies, where pleiotropic phenotypes are not observed,
lend themselves best to proof-of-principle RNAi-based thera-
peutics (Lane and McLean, 2008). Keratin disorders, which
primarily affect the epidermis, a highly accessible tissue, are
ideal model diseases for developing this type of therapeutic
(Lane and McLean, 2008; McLean and Moore, 2011).
Keratins form cytoplasmic intermediate filaments in
epithelial cells, which primarily function to protect these
cells from mechanical stress (Omary et al., 2004). According
to the Human Intermediate Filament Database (www.interfi-
l.org; Szeverenyi et al., 2008), 23 of the 54 human epithelial
keratin genes are linked to epithelial fragility disorders (Smith,
2003; McLean and Irvine, 2007; Lane and McLean, 2008).
Most causative variants are heterogeneous missense or small
in-frame insertion/deletion mutations that inhibit cytoskeletal
function via dominant-negative interference. Thus, treating
keratinizing disorders will require silencing, or limiting
the activity, of these mutant alleles. To date, a handful of
potentially therapeutic siRNAs have been identified for three
of these disorders: pachyonychia congenita (Hickerson et al.,
2008; Smith et al., 2008), epidermolysis bullosa simplex
(Atkinson et al., 2011), and Meesmann epithelial corneal
dystrophy (Liao et al., 2011). Indeed, one of these inhibitors
elicited therapeutic benefits in a phase I clinical trial
(Leachman et al., 2010). These ground-breaking studies have
clearly demonstrated that RNAi-based therapeutics are well
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suited for keratinizing disorders; unfortunately, each is linked
to a large number of different mutations in at least two
independent keratin genes. Therefore, standardizing down-
stream preclinical studies and subsequent clinical trials for
siRNAs targeting all of pathogenic mutations becomes
prohibitive.
To circumvent these downstream hurdles, we have
focused our attention on developing an RNAi-based thera-
peutic package for epidermolytic palmoplantar keratoderma
(EPPK). EPPK is unique because it is an autosomal-dominant
disorder caused only by mutations in human keratin K9
(KRT9; Smith, 2003; McLean and Irvine, 2007), which is
exclusively expressed in the suprabasal cells of palm and sole
epidermis (Langbein et al., 1993). EPPK presents as a well-
circumscribed epidermolytic keratoderma, and B90% of
cases carry a missense mutation in one of three hotspot
codons (www.interfil.org; Smith, 2003; McLean and Irvine,
2007).
The palmoplantar epidermis must withstand the greatest
mechanical stress in the body; therefore it is believed to have
adapted to express the greatest number of keratin genes (at
least 10; Swensson et al., 1998), which provide these cells
with the mechanical resilience to survive these arduous
conditions. The abundance of keratins here, and to a lesser
extent in other epidermal tissues, suggests that a degree of
functional redundancy occurs between coexpressed keratins.
This hypothesis is supported by several keratin knockout and
replacement studies that demonstrate keratin redundancies in
several epithelial tissues (Magin et al., 1998; Porter and Lane,
2003; Coulombe et al., 2004; Wong et al., 2005; Lu et al.,
2006). No recessive and/or loss-of-function mutations have
been identified in KRT9 (www.interfil.org; Szeverenyi et al.,
2008). Therefore, it is possible that complete ablation of
KRT9 expression may be tolerable.
Here, we present our initial studies developing a broad
preclinical RNAi-based therapeutic package for EPPK, which
contains generic KRT9 siRNA inhibitors and four individual
patient (allele)-specific siRNA inhibitors. We used a KRT9-
luciferase reporter assay to systematically identify the most
potent and specific lead inhibitors. These potencies and
specificities were independently verified in vitro under
disease modeling conditions using an innovative dual-tag
quantitative immunoblot assay. Finally, the efficacy of one of
our patient (allele)-specific siRNAs was confirmed in vivo in
an intact mouse epidermis using a mouse model.
RESULTS
RNAi-based inhibition of human KRT9 expression
Our initial objective was to develop siRNA inhibitors that
indiscriminately and specifically downregulate the expres-
sion of human KRT9. Six independent KRT9-targeting siRNAs
(siKRT9-1–6) were designed based on two criteria: they
target KRT9 transcripts outside of the mutation hotspot 1A
and 2B a-helical subdomain coding regions, and they display
strong sequence specificity for KRT9 transcripts compared
with all other type I and II keratins expressed in the human
epidermis (Figure 1a; see Supplementary Materials and
Methods online). A dual-luciferase reporter assay (Atkinson
et al., 2011) was used to assay the inhibitory potential of each
of these siRNAs. To this end, a full-length KRT9 complemen-
tary DNA firefly luciferase reporter construct (pfLUC-flKRT9/
WT) was co-transfected into AD293 cells with a Renilla
luciferase construct (for normalization) and each siRNA.
Optimal expression levels for pfLUC-flKRT9/WT and knock-
down potentials were defined using a positive control siRNA
targeting firefly luciferase (siLUC) and a nonspecific control
siRNA (NSC4). NSC4 did not affect fLUC-flKRT9/WT expres-
sion, whereas siLUC potently inhibited KRT9-luciferase
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Figure 1. Inhibition of wild-type K9 in AD293 cells. (a) Schematic diagram
of human keratin 9 (KRT9) mRNA and the positions where each short
interfering RNA (siRNA) targets KRT9. Black: protein-coding sequence; gray:
50 and 30 untranslated regions (UTRs). (b) AD293 cells were co-transfected
with a wild-type K9-luciferase reporter construct (pfLUC-flKRT9/WT) and
each of the KRT9-targeting siRNAs (siKRT9-1-6), a negative control siRNA
(NSC4), or a positive control siRNA (siLUC) over a concentration range of
0–6.25 nM. Luciferase activities were measured using the dual-luciferase
reporter assay 24 hours after transfection. Renilla luciferase activities were
used for normalization. Normalized firefly luciferase activities at each siRNA
concentration are expressed as percentages of firefly luciferase activity at
0 nM siRNA concentration. Error bars indicate SD of the mean from three
biological replicate experiments.
1628 Journal of Investigative Dermatology (2012), Volume 132
DM Leslie Pedrioli et al.
siRNA Therapeutics for EPPK
activity in a dose-dependent manner, displaying IC50 of
B70 pM (Figure 1b). Although all of the KRT9 siRNAs were
active and relatively potent inhibitors of fLUC-flKRT9/WT
reporter gene expression, displaying IC50 values ranging
between 100 and 250pM (data not shown), siKRT9-1 and
siKRT9-3 induced the strongest inhibitions (Figure 1b). Our
siRNA design criteria (see Supplementary Materials and
Methods online) required several mismatches between
these KRT9 siRNAs and other potential keratin transcripts.
Nevertheless, the off-target effects of one of the inhibitors
(siKRT9-3) were investigated in a human keratinocyte cell
line (HACATs) that expresses several keratins also found in
the palmoplantar epidermis. siKRT9-3-mediated knockdown
of endogenous keratins was not observed in cytoskeletal
extracts (Supplementary Figure S1 online), whereas striking
and specific reduction in endogenous keratin 6a (K6a) was
observed with a validated K6a inhibitor, siK6a-2 (Smith et al.,
2008).
Simultaneous inhibition of wild-type and mutant K9
protein synthesis
Unfortunately, the dual-luciferase assay only tested the
inhibitory capacities of siKRT9-1 and siKRT9-3 for wild-type
KRT9 in isolation. As EPPK patients express both wild-type
and dominant-negative mutant alleles of KRT9, it was
possible that allelic discrepancies could occur when attempt-
ing to simultaneously repress both in vivo. To test this,
KRT9 Flag-HA (K9-WT) and four dominant-negative mutant
KRT9 Strep-HA epitope-tagged (p.Arg163Trp (K9-R163W),
p.Arg163Gln (K9-R163Q), p.Met157Val (K9-M157V), and
p.Met157Thr (K9-M157T)) expression plasmids were gener-
ated. AD293 cells were co-transfected with no siRNA, 0.25
or 0.5 nM of siKRT9-1, -3, -5, or NSC4 siRNAs, and equal
amounts of pKRT9-WT/FlagHA and either pKRT9-R163W/
StrepHA, pKRT9-R163Q/StrepHA, pKRT9-M157V/StrepHA,
or pKRT9-M157T/StrepHA. A dual-tag quantitative immuno-
blotting assay was developed, using anti-Flag monoclonal
and anti-Strep-TagII polyclonal antibodies, to confirm inhibi-
tion of K9 protein translation. Fusion protein levels were
quantified using state-of-the-art infrared fluorochrome-
coupled secondary antibodies and direct infrared fluores-
cence detection with the LI-COR Odyssey Infrared Imaging
System (Fogarty et al., 2007). Although NSC4 had no effect
on wild-type or mutant K9 protein production, we confirmed
that siKRT9-1 and siKRT9-3 were potent inhibitors of
KRT9 and demonstrated equal inhibition of all KRT9 alleles
(Figure 2). Both siKRT9-1 and siKRT9-3 elicited 485%
knockdown at 0.25 nM (Figure 2) and complete inhibition
of expression at 0.5 nM (data not shown). Unexpectedly,
siKRT9-5, which showed the least potent inhibitory potential
in the luciferase assay, also proved to be an effective
repressor under these conditions (Figure 2).
The half-lives and abundances of these transiently
transfected K9 fusion proteins in AD293 cells are likely less
than those observed in vivo. Nevertheless, these data suggest
that they should effectively suppress endogenous KRT9
expression. To assess their long-term knockdown efficacy,
AD293 cells were co-transfected with pKRT9-WT/FlagHA,
pKRT9-R163W/StrepHA, and siKRT9-3 as described above.
Dual-tag immunoblotting confirmed near-complete knock-
down of both K9 fusion proteins 48 hours after transfection
(Supplementary Figure S2a online) and maintained inhibition
at 72 hours (Supplementary Figure S2b online). Surprisingly,
120 hours post-transfection production of K9-R163W and
K9-WT remained inhibited by 60% and 80%, respectively
(Supplementary Figure S2c online). Taken together, these
findings suggest that our generic KRT9 inhibitors should
sustainably inhibit de novo K9 protein synthesis in vivo.
In vitro screening for potent, allele-specific siRNA inhibitors
for EPPK patients
As studies detailing the phenotypic consequences associated
with homozygous and heterozygous loss of wild-type KRT9
are currently lacking, it is unclear whether ubiquitous
knockdown of KRT9 in EPPK patients will prove therapeutic.
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Figure 2. Simultaneous inhibition of wild-type and mutant K9 protein
synthesis. AD293 cells were transiently co-transfected with a FlagHA-tagged
wild-type K9 reporter construct (K9-WT), either no siRNA, 0.25 nM of a
nonspecific control (NSC4), or 0.25 nM siKRT9-1, -3, or -5, and (a) the
StrepHA-tagged mutant K9 reporter construct K9-R163W, (b) the StrepHA-
tagged mutant K9 reporter construct K9-R163Q, (c) the StrepHA-tagged
mutant K9 reporter construct K9-M157V, or (d) the StrepHA-tagged mutant K9
reporter construct K9-M157T. Immunoblotting of whole-cell lysates with
mouse a-Flag and rabbit a-StrepTagII antibodies and differential fluorescence
visualization using a LI-COR Odyssey scanner demonstrated simultaneous
reduction of both wild-type and mutant K9 protein synthesis following
siKRT9-1, -3, and -5 transfection. As a loading control, each membrane
was also probed with an a-b-actin antibody.
www.jidonline.org 1629
DM Leslie Pedrioli et al.
siRNA Therapeutics for EPPK
We, therefore, reasoned that allele-specific siRNA inhibitors
specifically targeting EPPK-associated single-nucleotide poly-
morphisms could function as patient-specific therapeutics
for EPPK. To date, 45 of the 74 reported EPPK mutations
occur within codons 163 (R163) and 157 (M157) of KRT9
(www.interfil.org; Szeverenyi et al., 2008). To develop
these alternative personalized RNAi-based therapies, siRNA
sequence walks (Hickerson et al., 2008; Atkinson et al.,
2011) were performed on four dominant-negative points:
K9-R163W and K9-R163Q, and K9-M157V and K9-M157T
(Reis et al., 1994; Covello et al., 1998). Arrays of 19
individual siRNA inhibitors were designed for each mutation
to define the optimal mutation-targeting nucleotide position
facilitating selective and potent silencing of each EPPK-
associated single-nucleotide polymorphism (Supplementary
Figures S3a–S6a online). Each siRNA within the array was
named according to the position of the mutation-specific
targeting nucleotide (Atkinson et al., 2011). Dual-luciferase
reporter assays were developed, where exon 1 of wild-type
KRT9 and the four mutations were cloned into the 30
untranslated region of firefly luciferase (see Supplementary
Materials and Methods online). We then screened all of the
siRNAs for their ability to selectively and potently inhibit
mutant, but not wild-type, KRT9 expression. AD293 cells
were co-transfected in quadruplicate with the KRT9 exon 1
constructs, Renilla luciferase (for normalization) and each
siRNA, NSC4, or siLUC (Supplementary Figures S3b–S6b
online). Sequence walks were repeated three times and the
average mutant and wild-type inhibitions, relative to 0 nM
siRNA, determined for the individual siRNAs (Supplementary
Figures S3c–S6c online).
siRNAs were considered allele specific if mutant allele
inhibition wasX50%, wild-type allele inhibition wasp50%,
the mutant and wild-type inhibition difference was X30%,
and the SD at the significant inhibition concentration was
p20%. Eight allele-specific siRNAs were identified that
specifically target the EPPK-associated mutations queried.
For K9-R163W, two inhibitors, siR163W-3 and siR163W-6,
strongly inhibited K9-R163W reporter allele expression and
successfully discriminated between K9-WT and K9-R163W
(Figure 3a). K9-R163Q reporter allele expression was speci-
fically repressed by two inhibitors, siR163Q-3 and siR163Q-
13, compared to K9-WT (Figure 3b). Inhibitors siM157V-11
and siM157V-16 specifically and potently inhibited K9-
M157V-luciferase expression, whereas a third inhibitor
(siM157V-6) moderately inhibited K9-M157V (Figure 3c).
Finally for M157T a single inhibitor, siM157T-16, showed
strong repressing characteristics but only moderate specificity
for K9-M157T (Figure 3d). The specificities of each allele-
specific siRNA were further confirmed by their inability
to silence the alternative codon mutation (Supplementary
Figure S7 online).
Preferential inhibition of mutant K9 protein synthesis
KRT9 Flag-HA and four KRT9 dominant-negative mutant
Strep-HA epitope-tagged alleles were used to further validate
the allele specificity and potency of these siRNAs under
pseudo-disease conditions. AD293 cells were transiently
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Figure 3. RNA interference (RNAi)-mediated independent mutant-specific inhibition of multiple K9 dominant-negative alleles. AD293 cells were co-
transfected with 0–6.25 nM of each of the 19 mutation-specific short interfering RNAs (siRNAs), or either of the control siRNAs (siLUC or NSC4), a Renilla
luciferase construct, and either wild-type K9 (K9-WT) or mutant K9-R163W (a), K9-R163Q (b), K9-M157V (c), or K9-M157T (d) firefly luciferase constructs.
Luciferase activities were measured 24hours after transfection and normalized using Renilla luciferase activities. Normalized firefly luciferase activities at
each siRNA concentration are expressed as percentages of activity at 0 nM siRNA. Error bars indicate SD of the mean for biological replicate experiments.
The most promising mutant-specific inhibitors for each dominant-negative allele are shown here; the complete siRNA walk data sets are shown in
Supplementary Figures S3–S6 online.
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co-transfected with equal amounts of pKRT9-WT/FlagHA
and either pKRT9-R163W/StrepHA, pKRT9-R163Q/StrepHA,
pKRT9-M157V/StrepHA, or pKRT9-M157T/StrepHA alone
or with 0.5 nM each of their respective lead inhibitors and
the dual-tag immunoblotting assays performed as described
above. In general, the potencies and allele specificities of
these siRNAs mirrored those observed in our initial dual-
luciferase siRNA sequence walks (Figure 4 and Supplemen-
tary Figures S8–S10 online). The exceptions to this were
siR163Q-3 (Supplementary Figure S9 online) and siM157V-6
(Supplementary Figure S10 online), whose inhibitory activ-
ities were not confirmed in this independent assay. When
transfection concentrations of siR163Q-3 and siM157V-6
were increased, similar knockdown of both the wild-type and
mutant alleles was observed (data not shown).
To quantitatively define the specificity and potency of the
remaining allele-specific siRNAs, the Flag-tag, Strep-TagII,
and b-actin band intensities were defined using GelEval
(www.frogdance.dundee.ac.uk) for all technical replicates in
each of the three biological replicate experiments (n¼ 9).
Both siR163W-3 and siR163W-6 potently inhibited K9-
R163W by 90% and 85%, respectively (Figure 4a and
Supplementary Figure S8 online). Nevertheless, siR163W-3
was the most allele discriminating of the two inhibitors,
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Figure 4. Validation of mutant-specific inhibition of K9 protein synthesis. AD293 cells were transiently co-transfected with pKRT9-WT/FlagHA (K9-WT)
and pKRT9-R163W/StrepHA (K9-R163W) (a), pKRT9-R163Q/StrepHA (K9-R163Q) (b), pKRT9-M157V/StrepHA (K9-M157V) (c), or pKRT9-M157T/StrepHA
(K9-M157T) (d) and 0.5 nM of the indicated short interfering RNA (siRNA). Immunoblotting of whole-cell lysates with a-Flag and a-StrepTagII antibodies
and differential fluorescence visualization using a LI-COR Odyssey scanner revealed preferential inhibition of mutant K9 protein synthesis by each of
the mutant-specific siRNAs (a–d; left panels). Quantitative analyses of a-Flag (wild-type) and a-StrepTagII (mutant) immunoblot signal intensities, relative
to b-actin, were used to quantify siRNA inhibition specificities and potencies (a–d; right panels). Mean relative abundances (n¼ 9) are shown, and error bars
indicate signal intensity SD. *Pp0.01; **Pp0.001; ***Pp0.0001.
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knocking down K9-WT by o35% (Figure 4a), while
450% knockdown was observed with siR163W-6 (Supple-
mentary Figure S8 online). siR163Q-13 specifically and
potently elicited 480% knockdown of K9-R163Q while
minimally affecting K9-WT expression (Figure 4b). siM157V-
11 (Figure 4c and Supplementary Figure S10 online) and
siM157T-16 (Figures 4d) proved to be the most promising
allele-specific inhibitors of K9-M157V and K9-M157T,
respectively. Finally, the off-target effects of these allele-
specific siRNAs were investigated in HACATs. The endo-
genous keratin profiles were not affected following 0.5 nM
transfection with siR163W-3, siR163Q-13, siM157V-11, or
siM157T-16, whereas transfection with 0.5 nM siK6a-2
resulted in near-complete knockdown of K6a (Supplementary
Figure S11 online).
Validation of mutant-specific siRNAs in mouse footpad
epidermis
Previous studies have independently demonstrated, using
high-pressure intradermal injections into the footpads of
mice (Gonzalez-Gonzalez et al., 2010), that gene- and
allele-specific siRNAs effectively repress the expression of
their respective keratin reporter genes in vivo (Hickerson
et al., 2008; Smith et al., 2008). Using this technique, we
assayed the inhibitory potential of our most discriminating
and potent allele-specific siRNA, siR163Q-13, in vivo
(Figure 5). The footpads of the mice were co-injected with
either the K9-R163Q (pfLUC-ex1KRT9/R163Q; n¼45 mice)
or the K9-WT (pfLUC-ex1KRT9/WT; n¼45 mice) luciferase
reporter constructs (Figure 5a; top and bottom panels,
respectively) and NSC4 siRNA (left paw; all animals) and
either siLUC (right paw; n¼ 22 mice) or siR163Q-13 (right
paw; n¼23 mice). Using our positive control siRNA (siLUC),
we confirmed that luciferase activities could be used as an
in vivo readout of siRNA-mediated knockdown (images not
shown). Moreover, we were able to confirm that siR163Q-13
targets and represses the expression of K9-R163Q more
frequently and efficiently than K9-WT (Figure 5a).
Although every precaution was taken to deliver equal
amounts of the reporter plasmids and siRNAs to each mouse
paw, it is extremely difficult to ensure consistent luciferase
activity in each animal. For this reason, large cohorts of
animals were used in each treatment group to obtain a
statistically robust data set. siLUC/NSC4 and siR163Q-13/
NSC4 luciferase activity ratios for K9-R163Q or K9-WT were
calculated, loge transformed to fit a normal distribution, and a
box-and-whiskers plot generated using R. Relatively equiva-
lent in vivo knockdown was observed when either K9-R163Q
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Figure 5. Inhibition of K9-R163Q/fLuc reporter gene expression by R163Q-13 short interfering RNA (siRNA) in vivo. (a) CD1 female mouse footpads were
co-injected with 15 mg pfLUC-ex1KRT9/R163Q (top panel) or pfLUC-ex1KRT9/WT (bottom panel) expression plasmids and 15mg NSC4 siRNA (left paw) or
siR163Q-13 (right paw). Footpad luciferase expression was determined 24hours after injection by whole-animal imaging using the Xenogen IVIS200 in vivo imaging
system. R/L values were calculated by dividing right paw luciferase light emissions (photons seconds–1 cm–2 sr–1) by left paw luciferase light emissions
(photons seconds–1 cm–2 sr–1); colored heat map depicts light emission intensity. (b) Box-and-whiskers plot of the loge-transformed in vivo K9-WT and K9-R163Q siLUC/
NSC4 and siR163Q-13/NSC4 luciferase light emission ratios. The Welch t-test was used to calculate P-values (P) in R. Asterisks (*) denote outliers within the data set.
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or K9-WT was co-injected with siLUC (Figure 5b). In contrast,
co-injection with siR163Q-13 more frequently and potently
inhibited K9-R163Q compared to K9-WT (Figure 5b).
A two-sample Welch’s t-test was used to determine whether
this preferential inhibition of K9-R163Q compared to
K9-WT was statistically significant. Although differences in
mutant and wild-type K9 fusion protein knockdown with
siLUC were not statistically significant (P¼0.8734), the
favored inhibition of K9-R163Q compared to K9-WT
observed in vivo with siR163Q-13 approaches statistical
significance (P¼ 0.0783). Thus, although inherently variable,
our pilot study with siR163Q-13 suggests that each of our
lead inhibitors should function as effective KRT9 repressors in
an intact epidermis and that their defined specificities should
be maintained in vivo.
DISCUSSION
The ‘‘holy grail’’ of translational research is to develop
bespoke, disease-tailored therapeutics for human diseases.
The discovery that exogenous siRNAs can be used to harness
the therapeutic potential of the endogenous RNAi pathway to
specifically and potently regulate and fine-tune gene expres-
sion provided a theoretically ideal path to personalized
therapeutics for some human diseases (Davidson and
McCray, 2011; Ketting, 2011). Although RNAi-based thera-
peutics are not ideal for all diseases, they are well suited
for inherited or acquired dominant-negative interference or
gain-of-function disease pathologies.
Our group and our collaborators have made great strides
toward the development of siRNA inhibitors for the keratin
disorders pachyonychia congenita (Hickerson et al., 2008;
Smith et al., 2008; Leachman et al., 2010), epidermolysis
bullosa simplex (Atkinson et al., 2011), and Meesmann
epithelial corneal dystrophy ((Liao et al., 2011), clearly
demonstrating that RNAi-based therapeutics are promising
treatment avenues. Unfortunately, pachyonychia congenita,
epidermolysis bullosa simplex, and Meesmann epithelial
corneal dystrophy are all linked to a large number of
mutations in at least two independent keratin genes. This
complicates downstream in vivo siRNA validation and
significantly narrows patient cohorts who would benefit from
the therapy. EPPK has advantages over other keratin disorders
because (1) it involves only one keratin gene; (2) the affected
area of the skin is limited and well circumscribed; (3) there
are many other keratins expressed in the affected tissue,
allowing for a generic, or gene-specific, approach; and
(4) there are important hotspot mutations, allowing an allele-
specific approach. Thus, we have developed a two-pronged
RNAi-based therapeutic package for EPPK. We have identi-
fied potent and highly specific generic (gene-specific) siRNAs
aimed at the KRT9 gene, as well as allele-specific inhibitors
targeting common hotspot mutations that exhibit no off-target
effects on endogenous epithelial cell keratin profiles.
Unfortunately, we have not yet been able to validate the
efficacies and specificities of our lead inhibitors under endo-
genous conditions. As a result, although these proof-of-
principle preclinical studies clearly identify effective KRT9
siRNA inhibitors, additional in vitro studies with primary
palmoplantar keratinocytes, as well as in vivo animal studies,
are required to determine therapeutically beneficial dosing
regimes for EPPK patients. Finally, EPPK is one of 430
recognized phenotypes produced by mutations in 23 keratin
genes (McLean and Moore, 2011), all of which share a
common pathomechanism. Therefore, one can reasonably
expect that if a therapeutic strategy is successful for one
of these diseases, it could be extrapolated to other skin
disorders, as well as many other dominant-negative genetic
disorders affecting other organ systems.
This study and others (Hickerson et al., 2008; Atkinson
et al., 2011) have described the development of personalized
siRNA therapies targeting a particular mutation using siRNA
sequence walks, which test all possible 19-mer siRNAs
targeting the point mutation of interest. So far, we have not
been able to predict the positions that will give allelic
discrimination based on primary target sequence alone. A
summary of the data from all published siRNA walks against
keratin mutations and the data presented here is shown in
Supplementary Table S1 online. These siRNA walks have
yielded allele-specific siRNAs, approximately two per muta-
tion. For each mutation, the pattern is highly reproducible; for
example, the K9 data presented here were consistent across
three biological replicate experiments, each containing
four technical replicates per data point. Thus, although the
pattern is sequence dependent, the rules appear extremely
complex. Understanding the rules that govern successful
allele-specific silencing would be advantageous as this
therapeutic strategy evolves; unfortunately, we have not
yet accumulated a sufficient number of data sets to
facilitate bioinformatics approaches to define these para-
meters. The only obvious rule that can be inferred from the
current combined data set is that the positions close to the
ends of the siRNA are ineffective, as positions 1 and 2 or
positions 17–19 have not produced mutation-specific
inhibitors (Supplementary Table S1 online). As even a
short stretch of 19 nucleotides has 42.7 1011 possible
sequence permutations, a systematic approach to deter-
mining these rules may prove difficult. Therefore, the
sequence walk methodology may be the best way to design
future reagents of this type.
Overall, this study has further expanded the repertoire
of potential siRNA therapeutic molecules for keratin disorders
to include gene-specific and allele-specific inhibitors for
the KRT9 gene in EPPK, which exhibits many unique and
attractive features as a model disease for application of siRNA
therapy within genodermatology. The potency, specificity,
and in vivo efficacy data presented here provide a preclinical
package for future development of a clinically applicable
therapy for EPPK.
MATERIALS AND METHODS
Cell culture
Human AD293 embryonic kidney cells (Invitrogen, Paisley, UK)
and HACAT human keratinocytes were maintained in DMEM
(Invitrogen) supplemented with 10% fetal calf serum (Invitrogen).
Cells were incubated at 37 1C with 5% CO2 supplement and
passaged following standard laboratory procedures.
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DNA constructs
Full-length wild-type KRT9-untagged (pKRT9-WT) and Flag-HA
(pKRT9-WT/FlagHA), and full-length p.Arg163Trp (pKRT9-R163W/
StrepHA), p.Arg163Gln (pKRT9-R163Q/StrepHA), p.Met157Val
(pKRT9-M157V/StrepHA), and p.Met157Thr (pKRT9-M157T/
StrepHA) mutant Strep-HA complementary DNAs, including the
50 and 30 untranslated regions, were synthesized and cloned into a
cytomegalovirus promoter–driven expression plasmid by DNA2.0
(Menlo Park, CA). pfLUC-ex1KRT9/WT, pfLUC-ex1KRT9/R163W,
pfLUC-ex1KRT9/R163Q, pfLUC-ex1KRT9/M157V, and pfLUC-
ex1KRT9/M157T firefly luciferase reporter constructs were generated
by PCR amplification and molecular cloning into the psiTEST-
Luc-target reporter plasmid (Yorkshire Bioscience, York, UK). See
Supplementary Materials and Methods online for further details.
siRNA design
The siDESIGN Center from Dharmacon RNAi technologies (Thermo
Scientific, http://www.dharmacon.com/designcenter/designcenterpage.
aspx) was used to identify candidate siRNAs targeting the coding
sequence and 30 untranslated region of KRT9 mRNA. The six siRNAs
(siKRT9-1–6) with the greatest number of mismatches between KRT9
and the other keratins queried were chosen for this study and
synthesized as previously described (Atkinson et al., 2011). A posi-
tive control siRNA (siLuc) targeting the firefly luciferase gene
(Atkinson et al., 2011) and a nonspecific control siRNA (NSC4)
(Hickerson et al., 2008) were also synthesized. To screen all possible
positions for the p.Arg163Trp (R163W), p.Arg163Gln (R163Q),
p.Met157Val (M157V), and p.Met157Thr (M157T) point mutations
within the 19-mer siRNA, mutation-specific sequence walk packages
containing 19 individual siRNAs were synthesized as previously
described (Hickerson et al., 2008; Atkinson et al., 2011).
Luciferase reporter assay
All siRNA screening studies were conducted as previously described
(Atkinson et al., 2011). Briefly, at 24 hours after plating, AD293 cells
were transfected with KRT9 firefly luciferase reporter constructs
(pfLUC-flKRT9/WT, pfLUC-ex1KRT9/WT, pfLUC-ex1KRT9/R163W,
pfLUC-ex1KRT9/R163Q, pfLUC-ex1KRT9/M157V, or pfLUC-ex1KRT9/
M157T), a Renilla luciferase expression plasmid, and 0–6.25nM of the
indicated siRNA using Lipofectamine 2000 (Invitrogen). The Dual-
Luciferase Reporter Assay (Promega, Southampton, UK) was performed
24hours after transfection following the manufacturer’s instructions. See
Supplementary Materials and Methods online for detailed protocols.
Immunoblotting
AD293 cells were transfected with 100 ng of pKRT9-WT/FlagHA,
100 ng of pKRT9-R163W/StrepHA, pKRT9-R163Q/StrepHA, pKRT9-
M157V/StrepHA, or pKRT9-M157T/StrepHA, and the indicated
siRNAs at final concentrations of 0.25 or 0.5 nM using Lipofectamine
2000 (Invitrogen). Lysates were generated in 1 denaturing
NuPAGE LDS sample buffer (Invitrogen) 48 hours after transfection,
resolved by SDS-PAGE, and transferred to nitrocellulose membranes.
Membranes were cut, blocked with western blot blocking buffer
(3% BSA, Tris-buffered saline/0.5% Tween 20, 1:100 Biotin Blocking
Buffer (IBA GmbH, Go¨ttingen, Germany)) for 3 hours at room
temperature, and incubated with primary antibodies diluted in
western blot blocking buffer overnight at 4 1C. The top halves of
all the membranes (450 kDa) were simultaneously probed with
1:1,000 mouse a-Flag M2 (F1804, Sigma-Aldrich, Gillingham, UK)
and 1:1,000 rabbit a-Strep-tag II (ab76949, Abcam, Cambridge, UK).
The bottom portions of the membranes (p50 kDa) were simulta-
neously probed with 1:1,000 rabbit a-Strep-tag II and 1:10,000
mouse a-b-actin (A1978, Sigma-Aldrich). Membranes were washed
extensively and probed with Alexa Fluor 680 goat a-rabbit IgG
(A-21076; Invitrogen, Life Technologies, Paisley, UK) and IRDye
800–conjugated goat a-mouse IgG (610-132-121; Rockland
Immunochemicals, Gilbertsville, PA) secondary antibodies, diluted
1:5,000 in 3% BSA/Tris-buffered saline/0.5% Tween 20 for 1 hour at
room temperature. Membranes were washed and scanned in the
700- and 800-nm channels using the Odyssey Infrared Imaging
System (LI-COR Biotechnology UK, Cambridge, UK). See Supple-
mentary Materials and Methods online for detailed protocols.
Colored images of each immunoblot were generated using Photo-
shop (Adobe Systems, San Jose, CA). Quantitative immunoblot
analyses were performed using the GelEval software (www.frogdance.
dundee.ac.uk) as described in the Supplementary Materials and
Methods online.
Mouse footpad injections and in vivo imaging
CD1 female mice (Charles River, Wilmington, MA or Harlan
Laboratories, Hillcrest, UK) were used for these experiments follow-
ing the guidelines for Animal Care of the National Institutes of Health
(NIH), Stanford University, TransDerm, and UK animal welfare act.
Mouse footpad injections were administered as described previously
(Hickerson et al., 2008; Smith et al., 2008; Gonzalez-Gonzalez
et al., 2010). Briefly, a total volume of 80 ml phosphate-buffered
saline containing 15 mg siRNA (NSC4, siLUC, or siR163Q-13) and
15 mg of firefly luciferase expression plasmid (pfLUC-ex1KRT9/WT or
pfLUC-ex1KRT9/R163Q) was intradermally injected with a 29-gauge
needle into the footpads of anesthetized mice. At 24 hours after
injection, luciferin (150mg/kg body weight) was administered by
intraperitoneal injection and the mice were imaged 10minutes after
injection using the IVIS200 in vivo imaging system (Xenogen product
from Caliper Life Sciences, Alameda, CA). The resulting light
emissions were quantied using LivingImage software 3.1 (Caliper
Life Sciences, Runcorn, UK). For the pfLUC-ex1KRT9/R163Q;
NSC4:siLUC and pfLUC-ex1KRT9/WT;NSC4:siLUC, the injections
were administered four times, with each treatment group containing
4 or 6 animals (22 animals/treatment). pfLUC-ex1KRT9/R163Q;
NSC4:siR163Q-13 and pfLUC-ex1KRT9/WT;NSC4:siR163Q-13 in-
jections were also administered four times, and each treatment group
contained 5 or 6 animals (23 animals/treatment). Statistical analyses
of these data were performed using R as described in the text.
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